SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Beautifull Nellore beef cattle grazing intensive tropical pasture in Brazil project
Opinion
AI Enables Companies to Break From the Herd in Drug Development
Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI could change that.
April 7, 2025
 · 
6 min read
 · 
Ruth Gross
Courtesy of Sarepta Therapeutics
Duchenne muscular dystrophy
Committee Recommends EU Trials of Sarepta’s Elevidys Continue, Day After Holds
One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the death of a U.S. teenager, a data monitoring committee concluded that they should continue unchanged.
April 4, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Illustration of a group of businessmen white-collar workers dismissed
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
 · 
1 min read
 · 
Angela Gabriel
Huge leg kick throw upset businessman out of office. Giant foot fire dismiss unhappy man employee of work. Job dismissal concept. Flat vector illustration, cartoon character.
Editorial
FDA Gutted Under Trump, RFK Jr., With More Than Half of Senior Leadership Now Gone
While it’s not unusual for certain positions to turn over with a new administration, the number of senior-level FDA staffers who have recently left the agency is unprecedented. The lack of communication, transparency and human decency is as well.
April 4, 2025
 · 
7 min read
 · 
Jef Akst
Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.
Immunology and inflammation
Aldeyra Shares Crash as Dry Eye Drug Gets Second Rejection from FDA
The FDA has asked for another well-controlled trial to establish the efficacy of reproxalap in dry eye disease.
April 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative photo poster picture collage collapsing dollar banknote arm holding cash money bankrupt decrease income funds loss.
Government
FDA Faces ‘Catastrophic Collapse’ as Massive Layoffs Endanger User Fee Program
The FDA derives just under half of its yearly funding from pharma user fees, which help support its operations and fund employee salaries. An analysis from AgencyIQ suggests that the agency is dangerously close to losing it all.
April 4, 2025
 · 
3 min read
 · 
Tristan Manalac
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Approvals
Amgen Wins Expansion for Uplizna as First Drug for IgG4-Related Disease
In the Phase III MITIGATE trial, Uplizna cut IgG4-related disease flares by 87% versus placebo.
April 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Business bankruptcy assistance concept. businessman on a paper boat and rescues a drowning man vector
Gene therapy
Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in preclinical studies has shown the ability to cross the blood-brain barrier.
April 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: AI robot holding biopharma-related items in hands
Artificial Intelligence
Secretive Biotech Xaira Hires Top AI Academic To Take His Work to ‘the Next Level’
Bo Wang is a renowned AI scientist at the University of Toronto. He’s bringing his open-source culture and computational biology to Xaira Therapeutics in June.
April 3, 2025
 · 
4 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS